6/29/21 19:37 | 6/29/21 | ARAV | Aravive, Inc. | | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | TX | DO | CEO,P | P | 5 | 5.35 | 0 | 1 | 10 | 11 | D | | | | | | | | | | | | | | |
12/7/20 20:00 | 12/4/20 | ARAV | Aravive, Inc. | | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | TX | DO | CEO,P | P | 46 | 5.77 | 0 | 8 | 374 | 10 | D | | | | | | | | | | | | | | |
6/18/14 16:46 | 6/16/14 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | S.dm | -7,818 | 105.01 | 0 | -74 | -75 | 24 | D | | | | | | | | | | | | | | |
6/18/14 16:46 | 6/16/14 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | M.dm | 844 | 11.95 | 0 | 71 | | 24 | D | | | | | | | | | | | | | | |
6/12/14 17:09 | 6/10/14 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | S.d | -183 | 104.58 | 0 | -2 | -6 | 28 | D | | | | | | | | | | | | | | |
9/18/13 21:43 | 7/19/13 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | S.a | -800 | 40.00 | 0 | -20 | -53 | 18 | D | | | | | | | | | | | | | | |
7/23/13 21:24 | 7/19/13 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | M.d | 182 | 9.11 | 0 | 20 | | 18 | D | | | | | | | | | | | | | | |
7/23/13 21:24 | 7/19/13 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | S.d | -423 | 40.00 | 0 | -11 | -37 | 18 | D | | | | | | | | | | | | | | |
11/21/11 17:23 | 11/17/11 | FURX | Furiex Pharmaceuticals, Inc. | DE | Health | Drug | Pharmaceutical Preparations | McIntyre Gail Frances | NC | O | SVP-Rese | P.d | 110 | 16.89 | 2 | 7 | 999% | 7 | D | | 28 | 10 | 8 | 15 | 10 | -4 | -9 | 7 | 10 | 11 | 12 | | |